# Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

> **NCT02475213** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 146 (actual)

## Conditions studied

- Melanoma
- Head and Neck Cancer
- Non Small Cell Lung Cancer
- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Enoblituzumab Schedule 1
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Enoblituzumab Schedule 2
- **BIOLOGICAL:** retifanlimab

## Key facts

- **NCT ID:** NCT02475213
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475213, "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02475213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*